Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SBTX Stock Alerts

Silverback Therapeutics (SBTX) Financials

Silverback Therapeutics logo
$8.56 +0.30 (+3.63%)
As of 05/1/2026
Compare
Annual Income Statements for Silverback Therapeutics

Annual Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -33 -20 -35 -54 8.00 -171
Consolidated Net Income / (Loss)		 -33 -20 -35 -54 8.00 -171
Net Income / (Loss) Continuing Operations		 -33 -20 -35 -54 8.00 -171
Total Pre-Tax Income 		-33 -20 -35 -54 8.29 -171
Total Operating Income		 -33 -19 -36 -68 -3.08 -179
Total Gross Profit		 0.00 5.51 1.32 0.03 88 84
Total Revenue		 0.00 5.51 1.32 0.03 89 84
Operating Revenue		 - 5.51 1.32 0.03 89 84
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.98 0.00
Total Operating Expenses		 33 25 37 68 91 264
Selling, General & Admin Expense		 8.34 4.69 18 47 72 230
Research & Development Expense		 25 20 18 20 20 13
Other Operating Expenses / (Income)		 - - - - - 20
Total Other Income / (Expense), net		 -0.03 -0.79 0.83 13 11 8.07
Other Income / (Expense), net		 - -0.79 0.97 13 11 8.07
Income Tax Expense		 - - - 0.00 0.29 -0.08
Basic Earnings per Share		 ($11.33) ($0.70) ($0.87) ($0.57) $0.08 ($1.74)
Weighted Average Basic Shares Outstanding		 2.91M 28.87M 39.96M 95.22M 96.94M 98.57M
Diluted Earnings per Share		 ($11.33) ($0.70) ($0.87) ($0.57) $0.08 ($1.74)
Weighted Average Diluted Shares Outstanding		 2.91M 28.87M 39.96M 95.22M 102.39M 98.57M
Weighted Average Basic & Diluted Shares Outstanding		 2.91M 34.93M 94.40M 96.50M 98.12M 99.30M

Quarterly Income Statements for Silverback Therapeutics

This table shows Silverback Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -15 -7.19 -10 -13 -19 49 -34 -45 -51 -41
Consolidated Net Income / (Loss)		 -17 -15 -7.17 -10 -13 -19 50 -34 -45 -51 -41
Net Income / (Loss) Continuing Operations		 -17 -15 -7.17 -10 -13 -19 50 -34 -45 -51 -41
Total Pre-Tax Income 		-17 -15 -7.17 -10 -13 -19 50 -37 -45 -51 -38
Total Operating Income		 -21 -18 -10 -13 -15 -22 47 -37 -48 -53 -41
Total Gross Profit		 0.01 0.00 - 0.00 0.50 2.07 86 6.88 16 33 29
Total Revenue		 0.01 0.00 - 0.00 0.50 2.07 87 7.97 16 33 28
Operating Revenue		 0.01 0.00 - 0.00 0.50 2.07 87 7.97 16 33 28
Total Cost of Revenue		 0.00 0.00 - 0.00 0.00 0.00 0.98 1.09 0.00 0.00 -1.09
Total Operating Expenses		 21 18 10 13 16 24 38 44 63 86 71
Selling, General & Admin Expense		 13 15 6.82 7.96 8.94 19 35 41 54 75 60
Research & Development Expense		 7.31 3.00 3.40 5.23 6.90 4.42 3.03 2.95 4.04 2.75 3.44
Total Other Income / (Expense), net		 3.23 3.11 3.06 2.90 2.82 2.62 3.03 0.00 2.73 2.04 3.30
Basic Earnings per Share		 ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52 ($0.35) ($0.46) ($0.52) ($0.41)
Weighted Average Basic Shares Outstanding		 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 96.94M 98.06M 98.36M 98.81M 98.57M
Diluted Earnings per Share		 ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52 ($0.35) ($0.46) ($0.52) ($0.41)
Weighted Average Diluted Shares Outstanding		 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 102.39M 98.06M 98.36M 98.81M 98.57M
Weighted Average Basic & Diluted Shares Outstanding		 95.57M 96.00M 96.50M 96.90M 96.94M 97.19M 98.12M 98.21M 98.83M 98.85M 99.30M

Annual Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 376 36 150 -140 -20 -9.50
Net Cash From Operating Activities		 -31 -18 -40 -59 14 -171
Net Cash From Continuing Operating Activities		 -31 -18 -40 -59 14 -171
Net Income / (Loss) Continuing Operations		 -33 -20 -35 -54 8.00 -171
Consolidated Net Income / (Loss)		 -33 -20 -35 -54 8.00 -171
Depreciation Expense		 0.64 0.21 0.03 0.07 0.08 1.37
Amortization Expense		 0.03 - 0.29 -6.85 -7.25 -5.52
Non-Cash Adjustments To Reconcile Net Income		 3.71 2.83 7.04 9.24 15 25
Changes in Operating Assets and Liabilities, net		 -2.63 -0.36 -13 -7.36 -1.81 -20
Net Cash From Investing Activities		 -0.92 -0.06 -0.20 -87 -106 57
Net Cash From Continuing Investing Activities		 -0.92 -0.06 -0.20 -87 -106 57
Purchase of Property, Plant & Equipment		 -0.92 -0.06 -0.20 -0.18 -0.56 -0.34
Purchase of Investments		 0.00 0.00 0.00 -272 -356 -242
Sale and/or Maturity of Investments		 - - 0.00 185 258 307
Other Investing Activities, net		 - - - 0.00 -7.50 -7.86
Net Cash From Financing Activities		 409 53 191 6.90 72 105
Net Cash From Continuing Financing Activities		 409 53 191 6.90 72 105
Issuance of Debt		 - - - - 0.00 96
Issuance of Common Equity		 258 0.17 0.57 6.90 3.02 5.68
Other Financing Activities, net		 -2.61 0.00 199 0.00 69 2.66
Cash Interest Paid		 - 0.58 0.37 0.00 0.00 2.45

Quarterly Cash Flow Statements for Silverback Therapeutics

This table details how cash moves in and out of Silverback Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 31 -58 10 -15 -19 3.03 11 -11 12 8.02 -18
Net Cash From Operating Activities		 -17 -13 -17 -6.71 -7.28 -14 42 -41 -40 -47 -43
Net Cash From Continuing Operating Activities		 -17 -13 -17 -6.71 -7.28 -14 42 -41 -40 -47 -43
Net Income / (Loss) Continuing Operations		 -17 -15 -7.17 -10 -13 -19 50 -34 -45 -51 -41
Consolidated Net Income / (Loss)		 -17 -15 -7.17 -10 -13 -19 50 -34 -45 -51 -41
Depreciation Expense		 0.02 0.02 0.01 0.01 0.02 0.02 0.03 0.28 0.28 0.39 0.42
Amortization Expense		 -1.75 -1.56 -1.73 -1.98 -1.90 -1.83 -1.54 -1.96 -1.47 -1.09 -1.00
Non-Cash Adjustments To Reconcile Net Income		 2.10 2.61 2.28 3.35 3.37 3.59 4.23 5.29 7.63 5.87 5.80
Changes in Operating Assets and Liabilities, net		 0.33 1.03 -11 2.21 3.76 2.88 -11 -10 -1.15 -1.07 -7.38
Net Cash From Investing Activities		 45 -47 26 -8.51 -13 17 -102 29 49 -45 24
Net Cash From Continuing Investing Activities		 45 -47 26 -8.51 -13 17 -102 29 49 -45 24
Purchase of Investments		 - -107 -34 -63 -88 -42 -163 -34 -31 -127 -49
Sale and/or Maturity of Investments		 45 60 60 55 75 61 67 64 80 89 75
Other Investing Activities, net		 - - - - - - -5.00 - - - -2.00
Net Cash From Financing Activities		 2.85 0.92 1.81 0.26 0.55 0.68 71 0.73 2.70 100 1.13
Net Cash From Continuing Financing Activities		 2.85 0.92 1.81 0.26 0.55 0.68 71 0.73 2.70 100 1.13
Issuance of Debt		 - - - - - - - - - - -1.49
Issuance of Common Equity		 2.85 0.92 1.81 0.26 0.55 0.68 1.53 0.73 2.70 0.48 1.78
Other Financing Activities, net		 - - - - - - - - - - 0.08

Annual Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 395 61 281 233 351 328
Total Current Assets		 391 61 278 232 334 285
Cash & Equivalents		 387 60 211 71 51 41
Short-Term Investments		 - 0.00 64 157 263 204
Accounts Receivable		 - 0.00 - 0.00 8.18 25
Inventories, net		 - - - 0.00 5.21 8.37
Prepaid Expenses		 4.09 0.67 3.32 3.37 6.89 6.19
Plant, Property, & Equipment, net		 1.62 0.07 0.33 0.57 1.07 2.47
Total Noncurrent Assets		 2.53 0.64 3.41 0.89 16 40
Intangible Assets		 - - - 0.00 7.37 14
Other Noncurrent Operating Assets		 2.53 0.64 3.41 0.89 8.42 26
Total Liabilities & Shareholders' Equity		 395 61 281 233 351 328
Total Liabilities		 12 17 8.55 2.43 94 213
Total Current Liabilities		 9.60 8.19 5.44 2.39 23 39
Accounts Payable		 2.58 3.11 4.93 2.15 23 38
Current Deferred Revenue		 - 1.46 0.28 0.00 0.56 0.61
Other Current Liabilities		 0.90 0.14 0.23 0.24 0.04 0.59
Total Noncurrent Liabilities		 2.33 8.49 3.11 0.04 71 174
Long-Term Debt		 - 4.93 - - 0.00 96
Noncurrent Deferred Revenue		 - 3.00 2.85 0.00 1.53 1.13
Other Noncurrent Operating Liabilities		 2.33 0.56 0.25 0.04 69 77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 383 -31 273 231 257 114
Total Preferred & Common Equity		 383 -31 273 231 257 114
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 383 -31 273 231 257 114
Common Stock		 480 11 349 362 380 409
Retained Earnings		 -97 -42 -77 -131 -123 -295
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.41 0.05 0.22 0.13

Quarterly Balance Sheets for Silverback Therapeutics

This table presents Silverback Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 294 271 271 259 249 228 222 218 327 313 373
Total Current Assets		 263 271 267 255 244 226 221 209 304 281 339
Cash & Equivalents		 219 203 88 119 61 56 37 40 40 52 60
Short-Term Investments		 39 63 177 133 181 168 182 165 236 189 229
Accounts Receivable		 - - - - - - - 0.77 9.30 25 36
Inventories, net		 - - - - - - - 0.72 7.27 8.74 7.78
Prepaid Expenses		 5.15 4.18 2.80 2.83 2.56 2.61 1.99 2.68 12 7.44 6.42
Plant, Property, & Equipment, net		 2.49 0.02 0.58 0.59 0.62 0.62 0.64 0.84 1.08 1.08 1.21
Total Noncurrent Assets		 28 0.25 3.26 3.12 3.47 0.73 0.59 7.97 22 31 33
Intangible Assets		 - - - - - - - 7.50 7.24 13 15
Other Noncurrent Operating Assets		 4.17 0.25 3.26 3.12 3.47 0.73 0.59 0.47 15 18 18
Total Liabilities & Shareholders' Equity		 294 271 271 259 249 228 222 218 327 313 373
Total Liabilities		 15 3.99 10 10 11 3.72 6.73 17 98 121 225
Total Current Liabilities		 11 3.99 9.84 10 11 3.72 6.73 17 28 46 51
Accounts Payable		 2.11 0.13 9.60 9.82 11 3.50 6.57 17 27 44 50
Current Deferred Revenue		 - - 0.01 0.00 0.00 0.00 0.00 0.00 0.54 - 0.53
Other Current Liabilities		 0.88 0.22 0.23 0.23 0.24 0.22 0.16 0.10 0.07 1.34 0.58
Total Noncurrent Liabilities		 4.07 0.00 0.20 0.15 0.09 0.00 0.00 0.00 71 76 174
Long-Term Debt		 - - - - - - - - - - 96
Noncurrent Deferred Revenue		 - - 0.00 0.00 0.00 0.00 0.00 0.00 1.34 - 1.27
Other Noncurrent Operating Liabilities		 4.07 0.00 0.20 0.15 0.09 0.00 0.00 0.00 69 76 77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 279 267 261 249 237 224 215 201 229 192 148
Total Preferred & Common Equity		 279 267 261 249 237 224 215 201 229 192 148
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 279 267 261 249 237 224 215 201 229 192 148
Common Stock		 511 517 353 358 362 366 369 374 386 394 401
Retained Earnings		 -230 -248 -92 -109 -124 -142 -154 -173 -157 -202 -253
Accumulated Other Comprehensive Income / (Loss)		 -1.55 -1.62 0.07 -0.18 -0.16 -0.12 -0.15 0.34 0.07 -0.05 -0.01

Annual Metrics And Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - 98,848,611.00
DEI Adjusted Shares Outstanding		 - - - - - 98,848,611.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -1.73
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -23 -14 -25 -47 -2.98 -126
Return On Investment Capital (ROIC_SIMPLE)		 - - - -20.48% -1.16% -59.64%
Earnings before Interest and Taxes (EBIT)		 -33 -20 -35 -54 8.29 -171
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -32 -20 -34 -61 1.11 -176
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.58 -30 -51 57 -148
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -2.85 -6.88 -1.50 2.40 -57 -34
Increase / (Decrease) in Invested Capital		 0.00 -4.04 5.39 3.90 -60 23
Book Value per Share		 $131.68 ($0.89) $7.57 $2.40 $2.65 $1.16
Tangible Book Value per Share		 $131.68 ($0.89) $7.57 $2.40 $2.57 $1.01
Total Capital		 384 53 273 231 257 211
Total Debt		 0.84 8.41 0.00 0.00 0.00 96
Total Long-Term Debt		 0.00 4.93 0.00 0.00 0.00 96
Net Debt		 -386 -52 -274 -228 -314 -149
Capital Expenditures (CapEx)		 0.92 0.06 0.20 0.18 0.56 0.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.67 -4.04 -2.13 0.98 -3.17 0.77
Debt-free Net Working Capital (DFNWC)		 382 56 272 229 311 246
Net Working Capital (NWC)		 381 53 272 229 311 246
Net Nonoperating Expense (NNE)		 9.90 6.63 9.82 7.10 -11 46
Net Nonoperating Obligations (NNO)		 -386 -52 -274 -228 -314 -149
Total Depreciation and Amortization (D&A)		 0.67 0.21 0.32 -6.78 -7.18 -4.16
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.56) ($0.87) ($0.57) $0.08 ($1.74)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 35.14M 39.96M 95.22M 96.94M 98.57M
Adjusted Diluted Earnings per Share		 $0.00 ($2.56) ($0.87) ($0.57) $0.08 ($1.74)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 35.14M 39.96M 95.22M 102.39M 98.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.56) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 34.93M 94.40M 96.50M 98.12M 99.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -14 -25 -47 -2.98 -126
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Silverback Therapeutics

This table displays calculated financial ratios and metrics derived from Silverback Therapeutics' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 98,848,611.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 98,848,611.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.42
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -14 -13 -7.16 -9.23 -11 -15 47 -26 -33 -37 -29
Return On Investment Capital (ROIC_SIMPLE)		 - - -3.10% -4.12% - - 18.38% -11.37% -17.33% -15.27% -13.78%
Earnings before Interest and Taxes (EBIT)		 -17 -15 -7.17 -10 -13 -19 50 -37 -45 -51 -41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -16 -8.88 -12 -14 -21 49 -39 -46 -52 -42
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -7.52 -11 -13 -11 -16 107 21 11 3.44 -52
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.66 -4.62 2.40 0.24 -3.50 -3.65 -57 -47 -48 -44 -34
Increase / (Decrease) in Invested Capital		 -0.25 -5.07 3.90 3.63 0.15 0.97 -60 -47 -44 -41 23
Book Value per Share		 $2.62 $2.48 $2.40 $2.32 $2.22 $2.07 $2.65 $2.33 $1.96 $1.49 $1.16
Tangible Book Value per Share		 $2.62 $2.48 $2.40 $2.32 $2.22 $2.00 $2.57 $2.26 $1.83 $1.35 $1.01
Total Capital		 249 237 231 224 215 201 257 229 192 244 211
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96 96
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96 96
Net Debt		 -252 -242 -228 -224 -219 -205 -314 -276 -240 -192 -149
Capital Expenditures (CapEx)		 0.03 0.04 -0.09 0.08 0.04 0.14 0.30 0.09 0.05 0.20 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.23 -8.62 0.98 -1.11 -4.73 -12 -3.17 0.51 -4.29 -0.22 0.77
Debt-free Net Working Capital (DFNWC)		 245 233 229 223 214 192 311 276 236 288 246
Net Working Capital (NWC)		 245 233 229 223 214 192 311 276 236 288 246
Net Nonoperating Expense (NNE)		 2.95 2.28 0.01 1.06 1.78 3.90 -2.74 7.92 12 14 12
Net Nonoperating Obligations (NNO)		 -252 -242 -228 -224 -219 -205 -314 -276 -240 -192 -149
Total Depreciation and Amortization (D&A)		 -1.73 -1.54 -1.72 -1.97 -1.89 -1.81 -1.52 -1.68 -1.19 -0.70 -0.59
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52 ($0.35) ($0.46) ($0.52) ($0.41)
Adjusted Weighted Average Basic Shares Outstanding		 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 96.94M 98.06M 98.36M 98.81M 98.57M
Adjusted Diluted Earnings per Share		 ($0.18) ($0.16) ($0.07) ($0.11) ($0.13) ($0.20) $0.52 ($0.35) ($0.46) ($0.52) ($0.41)
Adjusted Weighted Average Diluted Shares Outstanding		 94.91M 95.58M 95.22M 96.49M 96.83M 97.03M 102.39M 98.06M 98.36M 98.81M 98.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 95.57M 96.00M 96.50M 96.90M 96.94M 97.19M 98.12M 98.21M 98.83M 98.85M 99.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -13 -7.16 -9.23 -11 -15 33 -26 -33 -37 -29
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here are the core trends for ARS Pharmaceuticals (SPRY) based on the last four years of quarterly statements, focusing on the most recent four quarters (Q1–Q4 2025) and notable longer-term patterns. The highlights emphasize liquidity developments, profitability, and leverage dynamics that retail investors should watch.

  • Funding boost from 2025 equity financing: In 2025, ARS secured meaningful financing activity, notably a large net cash inflow from continuing financing activities in Q3 2025 of $100,045,000, largely from common equity issuance, improving near-term liquidity.
  • Strong asset cash inflows from investments: The company generated substantial cash via sale/maturity of investments in 2025, including $88,500,000 in Q3 2025 and $75,000,000 in Q4 2025, helping fund operations despite ongoing losses.
  • Ongoing, modest equity issuances added cash in 2025: Occasional equity issuances added cash in 2025 (Q2: $2,697,000; Q3: $479,000; Q4: $1,780,000), signaling continued capital-raising to support liquidity.
  • Gross profit remains positive in key periods: Q4 2025 shows Total Gross Profit of $29,181,000 on Total Revenue of $28,087,000, with Q3 2025 Gross Profit of $32,501,000 on $32,501,000 Revenue, indicating solid gross profitability in these quarters (notwithstanding operating losses).
  • Revenue variability across 2025: Operating Revenue ranged from $7,973,000 (Q1 2025) to $32,501,000 (Q3 2025), with Q4 2025 at $28,087,000, showing notable volatility quarter-to-quarter.
  • Persistent net losses in 2025: Net income attributable to common shareholders was -$41,324,000 in Q4 2025, -$51,150,000 in Q3 2025, -$44,883,000 in Q2 2025, and -$33,940,000 in Q1 2025, illustrating ongoing profitability challenges.
  • Very high SG&A expenses: SG&A expenses were a major drag in 2025 (Q4 2025: $59,955,000; Q3 2025: $74,750,000; Q2 2025: $54,312,000; Q1 2025: $41,104,000), dominating operating costs.
  • Debt leverage increased in 2025: Long-term debt rose to $96,229,000 in Q3 2025, introducing material leverage that did not exist in earlier quarters.
  • Deficit on retained earnings: Retained earnings remained deeply negative and widened in 2025 (Q3 2025: -$253,279,000; Q2 2025: -$202,128,000; Q1 2025: -$157,245,000; referenced negative trends continue from prior years).
  • Operating cash burn remains substantial: Cash flow from continuing operations was negative across all four 2025 quarters (Q1: -$40,742,000; Q2: -$39,592,000; Q3: -$47,047,000; Q4: -$43,485,000), indicating ongoing cash burn despite financing and investing inflows.
05/05/26 10:56 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Silverback Therapeutics' Financials

When does Silverback Therapeutics' financial year end?

According to the most recent income statement we have on file, Silverback Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Silverback Therapeutics' net income changed over the last 5 years?

Silverback Therapeutics' net income appears to be on an upward trend, with a most recent value of -$171.30 million in 2025, rising from -$32.95 million in 2020. The previous period was $8.00 million in 2024.

What is Silverback Therapeutics' operating income?
Silverback Therapeutics' total operating income in 2025 was -$179.45 million, based on the following breakdown:
  • Total Gross Profit: $84.28 million
  • Total Operating Expenses: $263.73 million
How has Silverback Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Silverback Therapeutics' total revenue changed from $0.00 in 2020 to $84.28 million in 2025, a change of 8,427,800,000.0%.

How much debt does Silverback Therapeutics have?

Silverback Therapeutics' total liabilities were at $213.39 million at the end of 2025, a 126.2% increase from 2024, and a 1,689.2% increase since 2020.

How much cash does Silverback Therapeutics have?

In the past 5 years, Silverback Therapeutics' cash and equivalents has ranged from $41.32 million in 2025 to $386.57 million in 2020, and is currently $41.32 million as of their latest financial filing in 2025.

How has Silverback Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Silverback Therapeutics' book value per share changed from 131.68 in 2020 to 1.16 in 2025, a change of -99.1%.


Related Companies

Financial statements for NASDAQ:SBTX last updated on 3/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel